MedTrace Logo

Intranasal AAV9-PHP.eB Gene Therapy in Cerebral Palsy (CP) & Hypoxic Ischemic Encephalopathy (HIE)

NCT07264166 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-03-23

No results posted yet for this study

Summary

This international study, organized by Healing Hope International, is an observational registry designed to collect real-world data on participants living with chronic hypoxic ischemic encephalopathy (HIE) who receive an emerging intranasal gene therapy based on the AAV9-PHP.eB viral vector.

The investigational therapy delivers a panel of 15 restorative genes that support brain repair, reduce inflammation, promote myelination, and improve neural communication. It is administered intranasally in one or three sessions by participating international clinical teams. Because the therapy is already being offered abroad, this registry does not assign treatment but instead follows participants who have received it as part of their existing medical care.

The GEN HOPE Study aims to understand how this gene therapy affects movement, cognition, spasticity, and seizure frequency over time. Families and clinicians will share outcomes such as changes in gross motor function (GMFM-66/88), cognitive assessments (Bayley or WISC tests), and quality-of-life measures. Information on safety, laboratory results, MRI findings, and caregiver-reported experiences will also be collected.

By combining data from multiple countries, the registry seeks to evaluate whether this novel gene based approach can meaningfully improve daily function and comfort for participants with chronic HIE. Results will guide future clinical trial development and help define safe and effective standards of care for regenerative neurologic therapies.

Conditions

  • Hypoxic Brain Damage
  • Hypoxic Ischaemic Encephalopathy (HIE)
  • Hypoxic Ischaemic Encephalopathy Due to Cardiac Arrest
  • Hypoxic Ischemic Encephalopathy of Newborn
  • Cerebral Palsy
  • Cerebral Palsy (CP)
  • Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment
  • Cerebral Palsy Quadriplegic
  • Cerebral Palsy Spastic Diplegia

Sponsors & Collaborators

  • Healing Hope International

    lead OTHER

Principal Investigators

  • Dr. Anna Lara Kattan, MD: Regenerative Medicine · Stem Solutions

Eligibility

Min Age
2 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2032-01-01
Completion
2032-06-15

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07264166 on ClinicalTrials.gov